Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03838185 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147
A Phase 1 study of Alzheimers Disease, sponsored by Abrexa Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT03838185: Completed Phase 1 study of Alzheimers Disease, sponsored by Abrexa Pharmaceuticals.
NCT03838185 is a Phase 1 study of Alzheimers Disease that has completed, run by Abrexa Pharmaceuticals. The registered enrollment target is 64 participants, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03838185, a Phase 1 study of Alzheimers Disease, has completed, sponsored by Abrexa Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
This Phase I clinical study is a randomized, double-blind, placebo-controlled, parallel-design study to thoroughly assess the safety profile and PK properties of J147 in healthy subjects. The study will include single ascending dose (SAD) in healthy young and elderly subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG J147
Study Locations (1)
Kansas
- Vince & Associates Clinical Research, Inc. - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2019-01-22 |
| Est. Completion | 2020-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03838185
The ClinicalTrials.gov registry entry for NCT03838185 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (98% lower). The listed sponsor is Abrexa Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03838185 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT03838185 about?
NCT03838185 is a clinical study titled "Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147". This Phase I clinical study is a randomized, double-blind, placebo-controlled, parallel-design study to thoroughly assess the safety profile and PK properties of J147 in healthy subjects. The study will include single ascending dose (SAD) in healthy young and elderly subjects.
What is the current status of trial NCT03838185?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2019-01-22. Estimated completion is 2020-02-01.
What conditions does trial NCT03838185 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT03838185?
The interventions under investigation include: Placebo (DRUG), J147 (DRUG).
Who is sponsoring clinical trial NCT03838185?
This trial is sponsored by Abrexa Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03838185 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
RECRUITING · Phase 1
-
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
RECRUITING · Phase 1
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
RECRUITING · Phase 1
-
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
RECRUITING · Phase 1
-
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.